triggering receptor expressed on myeloid cells like 2Genealiases: C6orf76 · TLT-2 · TLT2 · dJ238O23.1
Q-omics provides the consensus-scored TREML2 profile across patient tissues and cancer cell-line models. TREML2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TREML2 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TREML2 RNA expression shows 15,534 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where TREML2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TREML2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TREML2 survival associations across molecular data types. TREML2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TREML2 RNA expression–survival associations across cancer types. High TREML2 expression shows unfavorable associations in COAD, LAML and ACC, but favorable associations in SKCM, HNSC and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TREML2 RNA expression.
This table summarizes TREML2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TREML2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TREML2 shows lower tumor expression in LUSC and LUAD and higher tumor expression in HNSC, KIRC, STAD and ESCA. The HNSC box plot shows higher TREML2 RNA expression in tumor versus normal tissue (log2 FC = +0.432, t-test p < 0.001).
This table shows molecular features associated with TREML2 in patient tissues and cancer cell lines. In patient samples, TREML2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TREML2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
